NASDAQ:SVA Sinovac Biotech (SVA) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free SVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$6.47▼$6.4750-Day Range$6.47▼$6.4752-Week Range$5.73▼$8.75VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sinovac Biotech alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Sinovac Biotech Stock (NASDAQ:SVA)Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.Read More Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> SVA Stock News HeadlinesFebruary 21, 2024 | businesswire.comSinovac Amends Shareholder Rights PlanFebruary 21, 2024 | businesswire.comSinovac Amends Shareholder Rights PlanMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.January 18, 2024 | markets.businessinsider.comSinovac Board Rejects Partial Tender Offer By Alternative Liquidity Index - Quick FactsJanuary 3, 2024 | msn.comNepal to destroy 4 million doses of China’s Sinovac shots as China refuses to take back vaccinesDecember 9, 2023 | morningstar.comSinovac Biotech Ltd SVANovember 24, 2023 | msn.comPneumonia outbreak in China is no reason for alarm: WHOSeptember 11, 2023 | finance.yahoo.comSINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 InjectionMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.September 5, 2023 | businesswire.comSinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender OfferAugust 29, 2023 | finance.yahoo.comSinovac Confirms Receipt of an Unsolicited Partial Tender OfferAugust 28, 2023 | finance.yahoo.comSinovac Announces Change of Legal Representative of Sinovac BeijingAugust 15, 2023 | finance.yahoo.comSINOVAC Reports Unaudited First Half of 2023 Financial ResultsJuly 20, 2023 | uk.finance.yahoo.comSVA - Sinovac Biotech Ltd.May 10, 2023 | finance.yahoo.comSINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 VaccinesMay 1, 2023 | finance.yahoo.comSINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-FMarch 2, 2023 | thestreet.comSinovac Biotech Stock Soars (SVA)December 29, 2022 | finance.yahoo.comSINOVAC Reports Unaudited First Half of 2022 Financial ResultsDecember 15, 2022 | msn.comWHO chief hopeful COVID emergency will end next yearNovember 4, 2022 | markets.businessinsider.comSINOVAC Biotech Receives WHO Prequalification For Varicella VaccineNovember 4, 2022 | finance.yahoo.comSINOVAC Varicella Vaccine Prequalified by WHOOctober 28, 2022 | finance.yahoo.comSINOVAC to Showcase Products at CPHI FrankfurtOctober 1, 2022 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVASeptember 23, 2022 | finance.yahoo.comSinovac Biotech Ltd. (SVA)September 6, 2022 | finance.yahoo.comSINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in ChileAugust 20, 2022 | stockhouse.com1Globe Capital Deadline AlertAugust 18, 2022 | reuters.comSinovac Biotech LtdSee More Headlines Receive SVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinovac Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SVA CUSIPN/A CIK1084201 Webwww.sinovac.com Phone86-10-5693-1800Fax86-10-5693-1800Employees4,275Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.89 Quick Ratio9.74 Sales & Book Value Annual Sales$1.49 billion Price / SalesN/A Cash Flow$1.13 per share Price / Cash Flow5.73 Book Value$127.76 per share Price / Book0.05Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Weidong Yin (Age 56)Chairman, CEO, Pres, MD, GM & Sec. Ms. Nan Wang (Age 55)CFO & VP of Bus. Devel. Mr. Qiang Gao (Age 44)VP & COO Key CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors SVA Stock Analysis - Frequently Asked Questions When is Sinovac Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our SVA earnings forecast. What other stocks do shareholders of Sinovac Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sinovac Biotech investors own include Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AT&T (T), Tesla (TSLA), VIVUS (VVUS), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Micron Technology (MU) and TherapeuticsMD (TXMD). This page (NASDAQ:SVA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.